DRTS
Alpha Tau Medical Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$15.03
+2.80%Aug 31, 2026, 12:00 UTC
Alpha Tau Medical completed patient enrollment in its multicenter IMPACT pilot study of Alpha DaRT for unresectable pancreatic cancer, expanding enrollment from 12 to 48 patients.
Source:Jul 21, 2026, 12:30 UTC
Alpha Tau Medical reported positive clinical data for Alpha DaRT in combination with pembrolizumab in head and neck cancer at the AHNS conference on July 21, 2026.
Source:Jul 15, 2026, 12:30 UTC
Alpha Tau successfully treated the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in its ADMIRE study at Banner MD Anderson Cancer Center.
Source:Jun 3, 2026, 12:30 UTC
Alpha Tau Medical Ltd. and Tolmar International Ltd. announced a strategic collaboration to bring Alpha DaRT therapy to U.S. urological cancer patients, with Tolmar making an initial $15M manufacturing investment, a $20M equity infusion, and up to $161.5M in milestones.
Source: